FKONCO

Fresenius Kabi Oncology Limited has informed the Exchange that the Company shall be publishing audited results for financial year ended March 31, 2012 within 60 days of the end of the financial year. Therefore, the unaudited results will not be adopted/ published separately.

Fresenius Kabi Oncology Limited has informed the Exchange that the Board of Directors of the Company has taken on record the resignation of Dr. Anand C. Burman as the Non-Executive Director of the Company w.e.f. February 02, 2012.

Fresenius Kabi Oncology Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on February 02, 2012, has taken on record the resignation of Dr. Anand C. Burman as the Non - Executive Director of the Company w.e.f. February 02, 2012.

Fresenius Kabi Oncology Limited has submitted to the Exchange the Standalone Financial Results for the period ended December 31,2011.

Fresenius Kabi Oncology Limited has informed the Exchange that the Company has obtained requisite Shareholders approval through Postal Ballot, pursuant to Section 192A of the Companies Act, 1956 on the Special Resolution for appointment of Mr. Peter F. Nilsson as the Managing Director & CEO of the Company w.e.f. October 20, 2011 for a period of two years.

Fresenius Kabi Oncology Limited has submitted to the Exchange a copy of notice pursuant to Section 192A of the Companies Act, 1956 read with the Companies (Passing of Resolution by Postal Ballot) Rules, 2011, in respect of the resolution to be passed through Postal Ballot : Special Resolution for appointment of Mr. Peter F. Nilsson as the Managing Director & CEO of the Company.

Fresenius Kabi Oncology Limited has submitted to the Exchange the Standalone Financial Results for the period ended September 30,2011.

Fresenius Kabi Oncology Limited has informed the Exchange regarding the outcome of Annual General Meeting of the Company held on August 11, 2011.

Fresenius Kabi Oncology Limited has submitted to the Exchange the Standalone Financial Results for the period ended June 30,2011.

Fresenius Kabi Oncology Limited had informed the Exchange regarding disinvestment of Fresenius Kabi Oncology Ltd's entire shareholding in Fresenius Kabi Oncology Plc, UK to Fresenius Kabi, Germany and its affiliates. The Company has now informed the Exchange that the Company has finalized and executed the share purchase agreement with Fresenius Kabi AG w.e.f. June 24, 2011.In terms of the aforesaid share purchase agreement, Company's entire shareholding of 171400000 equity shares of GBP 0.10 each in Fresenius Kabi Oncology Plc, UK now stands transferred to Fresenius Kabi AG (Germany) at the bo

Fresenius Kabi Oncology Limited has informed the Exchange that the Board of Directors at their meeting held on May 26, 2011 decided (1) To convene the Annual General Meeting of the Company on August 11, 2011. (2) Fixed the Book Closure period from August 01, 2011 to August 11, 2011 (both days inclusive).

Fresenius Kabi Oncology Limited has informed the Exchange that the Board of Directors at its meeting held on May 26, 2011 has: (1) Not recommended any dividend for the year. (2) Recommended the re-appointment of Dr. Michael Schonhofen as a Director liable to retire by rotation.(3) Recommended the re-appointment of Mr. Nitin Potdar as a Director liable to retire by rotation. (4) Recommended the re-appointment of Mr. Gerrit Steen as a Director liable to retire by rotation.(5) Recommended the appointment of Mr. Mats Christer Henriksson as a Director liable to retire by rotation in terms of Sectio

Fresenius Kabi Oncology Limited has informed the Exchange regarding a press release dated May 26, 2011 , titled " FRESENIUS KABI ONCOLOGY LIMITED TO FOCUS ON CONTRACT R & D AND MANUFACTURING ACTIVITIES."

Fresenius Kabi Oncology Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended March 31,2011.

Fresenius Kabi Oncology Limited has informed the Exchange that since the Company shall be publishing audited results for financial year ended March 31, 2011 within 60 days of the end of the financial year; the unaudited results will not be adopted/ published separately.

Fresenius Kabi Oncology Limited has submitted to the Exchange the Standalone Financial Results for the period ended December 31,2010.

Fresenius Kabi Oncology Limited has informed the Exchange that Dabur Pharma (Thailand) Co. Ltd, the wholly owned subsidiary of Fresenius Kabi Oncology Limited in Thailand, has been dissolved w.e.f. January 14, 2011 as per the applicable laws in Thailand.

Fresenius Kabi Oncology Limited has submitted to the Exchange the Standalone Financial Results for the period ended September 30,2010.

Fresenius Kabi Oncology Limited has informed the Exchange that "Fresenius Kabi Oncology Ltd. has renewed the tenure of Memorandum of Understanding entered into with our RTA (MCS Ltd) on January 12, 2004 for a further period of one year from January 12, 2010 to January 11, 2011 on the existing terms and conditions."

Fresenius Kabi Oncology Limited has informed the Exchange regarding the outcome of Annual General Meeting of the Company held on July 29, 2010.

Fresenius Kabi Oncology Limited has informed the Exchange that the Board of Directors of the Company in its meeting held on July 29, 2010, inter alia, took note of the following : (1) Dissolution of Fresenius Kabi Oncology Inc. (USA), the Indirect Wholly Owned Subsidiary in USA w.e.f. March 24, 2010.

Fresenius Kabi Oncology Limited has submitted to the Exchange a copy of the Notice of the Annual General Meeting of the members of the company to be held on July 29, 2010.

Fresenius Kabi Oncology Limited has informed the Exchange that the Board of Directors at their meeting held on May 28, 2010 decided (1) To convene the Annual General Meeting of the Company on July 29, 2010. (2)Fixed the Book Closure period from July 19, 2010 to July 29, 2010 (both days inclusive).

Fresenius Kabi Oncology Limited has informed the Exchange that the Board of Directors at its meeting held on May 28, 2010 has: (1) Decided to convene the Annual General Meeting of the Company on July 29, 2010. (2) Not recommended any dividend for the year. (3) Recommended the re-appointment of Dr. Anand C. Burman as a Director liable to retire by rotation.(4) Recommended the re-appointment of Mr. Dilip G. Shah as a Director liable to retire by rotation. (5) Recommended the re-appointment of Mr. Rakesh Bhargava as a Director liable to retire by rotation.

Fresenius Kabi Oncology Limited has informed the Exchange that in terms of amendment vide SEBI circular dated April 5, 2010 the Company hereby confirms to publish the annual audited results for financial year ended March 31, 2010 within 60 days from the end of financial year.

Fresenius Kabi Oncology Limited has informed the Exchange regarding a release dated April 01, 2010 titled "Fresenius Kabi Oncology Limited enters into a licensing and settlement agreement with Sanofi-Aventis". A copy of the release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/fkonco_rel_05042010.zip target=NEW> For more details click here.</a>

Fresenius Kabi Oncology Limited has informed the Exchange that:"The Company shall be publishing audited results for financial year ended 31st March 2010 within three months from the end of financial year; the unaudited results will not be adopted/ published separately".

Fresenius Kabi Oncology Limited has informed the Exchange that with a view to integrate its operations in Thailand, the Board of Directors of Fresenius Kabi Oncology Limited has on February 22, 2010 accorded its approval for: (1) Subject to compliance of applicable laws in Thailand, transfer the entire business, including all assets and liabilities of its wholly owned subsidiary in Thailand i.e. Dabur Pharma (Thailand) Company Limited at Fresenius Kabi (Thailand) Limited at the book value. (2) Subsequently dissolve/liquidate Dabur Pharma (Thailand) Company Ltd. as per the applicable laws in Th

Fresenius Kabi Oncology Limited has informed the Exchange vide its letter dated January 20, 2010 that : In the recently concluded meeting of the Board of Directors of the Company, the following matters have been considered and approved / noted : 1) Mr. Mats Christer Henriksson has been appointed as the Director w.e.f. January 20, 2010, in order to fill up the casual vacancy necessitated due to resignation of Mr. John Robert Ducker from the Board of Directors of the Company; 2) The Board also took note about the execution of a long term lease agreement for shifting of Corporate Office and R & D

Fresenius Kabi Oncology Limited has informed the Exchange that "Mr. John Robert Ducker, Director of the Company, has resigned from the Directorship of the Company w.e.f. January 13, 2010".

Fresenius Kabi Oncology Limited has informed the Exchange that in the meeting of the Board of Directors of the Company held on July 30, 2009, the following matter has been considered and approved: Further expansion of plant at D-35, Industrial Area, Kalyani, District Nadia, West Bengal 741 235, with an estimated cost of INR 230 million.

Fresenius Kabi Oncology Limited has informed the Exchange regarding the outcome of Annual General Meeting of the Company held on July 29, 2009. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/FRESENIUS_OAGM_30072009.zip target=NEW> For more details click here.</a>

Fresenius Kabi Oncology Limited has submitted to the Exchange a copy of Notice of the Annual General Meeting of the Shareholders of the Company to be held on July 29, 2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Fresenius_AGM_07072009.zip target=NEW> For more details click here.</a>

Fresenius Kabi Oncology Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on April 30, 2009 have : 1) Decided to convene the Annual General Meeting of the Company on July 29, 2009. 2) Fixed the Book Closure period from July 15, 2009 to July 29, 2009 (both days inclusive). 3) Not recommended any dividend for the year. 4) Approved the alteration of Articles of Association of the Company. 5) Recommended the re-appointment of Dr. Naresh Trehan, as a Director liable to retire by rotation. 6) Recommended the appointment of Dr. Satish B. Kulkarni, Managi

Fresenius Kabi Oncology Limited had informed the Exchange that the Board of Directors of the Company, by way of circular resolution passed on March 20, 2009 has, pursuant to the receipt of shareholder consent, approved the allotment of 1550255 equity shares of Rs. 1/- each at a premium of Rs. 44.95/- per share on a preferential basis, on receipt of Rs 71,249,719.80/- as the total consideration, to Atlas-Vermoegensverwaltungs-GmbH, Kaiserstrasse 16, 60311 Frankfurt, Germany. After the aforesaid allotment, public shareholding in the Company stands increased to 10% of the total issued and paid up

Fresenius Kabi Oncology Limited has informed the Exchange that the Board of Directors of the Company, by way of circular resolution passed on March 20, 2009 has, pursuant to the receipt of shareholder consent, approved the allotment of 1550255 equity shares of Rs. 1/- each at a premium of Rs. 44.95/- per share on a preferential basis, on receipt of Rs 71,249,719.80/- as the total consideration, to Atlas-Vermoegensverwaltungs-GmbH, Kaiserstrasse 16, 60311 Frankfurt, Germany. After the aforesaid allotment, public shareholding in the Company stands increased to 10% of the total issued and paid up

Fresenius Kabi Oncology Limited has informed the Exchange that at the Extra-Ordinary General Meeting of the Company held on March 13, 2009, the shareholders have accorded consent to the Board of Directors of the Company to offer, issue and allot 1550255 number of equity shares of the Company, constituting 0.99% of the pre-issue (existing) issued and paid up share capital of the Company ("Shares") to Atlas- Vermoegensverwaltungs- GmbH, on a preferential basis, in such manner and on such other terms and conditions as may be determined by the Board of Directors in its absolute discretion at a pri

Dabur Pharma Limited has submitted to the Exchange a copy of the Notice along with Explanatory Statement of the Extra Ordinary General Meeting to be held on March 13, 2009 to transact the Special business mentioned in the Notice. The copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/daburpharma_NOTEGM_17022009.zip target=NEW> For more details click here.</a>

Dabur Pharma Limited has informed the Exchange that the Board of Directors of the Company by way of circular resolutions passed on February 12, 2009 has :(1) Subject to receipt of shareholders' consent and other applicable regulatory approvals, approved the offer and issue of 15,50,255 number of equity shares of the Company constituting 0.99% of the pre-issue (existing) issued and paid up share capital of the Company ("Shares") to Atlas-ermoegensverwaltungs-GmbH, on a preferential basis at a price determined in accordance with the SEBI (Disclosure and Investor Protection) Guidelines, 2000. (2)

Members of the Exchange are hereby informed that the name of Dabur Pharma Limited shall be changed to Fresenius Kabi Oncology Limited and the trading symbol of the Company be changed from DABURPHARM to FKONCO w.e.f. February 19, 2009.

Dabur Pharma Limited has informed the Exchange that in the meeting of the Board of Directors of the Company, held on January 29, 2009, the following matters have been considered and approved: 1) Shifting of Registered Office of the Company from "3, Factory Road, Adj. Safdarjung Hospital, New Delhi - 110 029" to "B - 310, Som Datt Chambers - I, Bhikaji Cama Place, New Delhi - 110 066" w.e.f. January 29, 2009. 2) Expansion of plant at D - 35, Industrial Area, Kalyani, District Nadia, West Bengal 741 235, with an estimated cost of Rs. 72.4 crores.

Dabur Pharma Limited has informed the Exchange that Central Government has accorded its approval for change of name of the Company from "Dabur Pharma Limited" to "Fresenius Kabi Oncology Limited" vide SRN A53589735 w.e.f. January 09, 2009.

Dabur Pharma Limited has informed the Exchange that :"The Company has obtained requisite Shareholders approval through Postal Ballot pursuant to Section 192A of the Companies Act, 1956 on the Special resolution for change of name of the company from "Dabur Pharma Limited" to "Fresenius Kabi Oncology Limited" pursuant to Section 21 and other applicable provisions of the Companies Act, 1956".

Dabur Pharma Limited has informed the Exchange that UK's Medicines and Healthcare products Regulatory Agency (MHRA) Licensing Authority has granted the marketing authorization for Bicalutamide 50mg tablet to the Company.

Dabur Pharma Limited has informed the Exchange that Pursuant to the provisions of Section 192A of the Companies Act, 1956 read with the Companies (Passing of the Resolution by Postal Ballot) Rules, 2001, the Company is seeking the consent of its members through Special Resolution proposed to be passed by Postal Ballot in respect of Special resolution for change of name of the Company from Dabur Pharma Limited to Fresenius Kabi Oncology Limited. The Company has appointed Ms. Kiran Sharma, Practicing Company Secretary as the Scrutinizer for conducting the postal ballot process. The duly complete

Dabur Pharma Limited has informed the Exchange that the Company has appointed new CFO Mr. Peter Neilsson, w.e.f. November 01, 2008 in place of Mr. Shailendra Tandon, who has relinquished his office from the same date. Further, the company has informed the Exchange that the e-mail of Investor Grievance has changed as follows: avaneesh.singh@daburpharma.com.

Dabur Pharma Limited has informed the Exchange regarding a press release dated October 23, 2008, titled "Dabur Pharma Declares Financial Results". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/DABUR_PR_24102008.zip target=NEW> For more details click here.</a>

Dabur Pharma Limited has informed the Exchange that in the meeting of the Board of Directors of the Company held on October 23, 2008, the following matters have been considered and approved/ noted: (1) Change of name of the Company from Dabur Pharma Ltd to Fresenius Kabi Oncology Ltd. subject to approval of Shareholders and Statutory Authorities. (2) Change of name of the Wholly Owned Subsidiary Companies, subject to necessary approvals: (a) Existing Name - Dabur Oncology Plc. (UK) : Proposed Name - Fresenius Kabi Oncology Plc. (b) Existing Name - Dabur Pharma (Thailand) Co. Ltd. : Proposed N

Dabur Pharma Limited has informed the Exchange that the Company has obtained requisite Shareholders approval through Postal Ballot pursuant to Section 192A of the Companies Act, 1956 on the Ordinary resolution for appointment and remuneration of Dr. Satish Kulkarni as the Managing Director and CEO of the Company w.e.f. August 11, 2008 for a period of five years.

Dabur Pharma Limited has informed the Exchange that pursuant to the provision of Section 192A of the Companies Act, 1956, read with the Companies (Passing of the Resolution by Postal Ballot) Rules, 2001, the Company is seeking the consent of its members through postal ballot for the following : 1) Ordinary Resolution for appointment and terms and conditions of Dr. Satish Kulkarni as Managing Director & CEO of the Company. The Company has appointed Ms. Kiran Sharma, Practicing Company Secretary as the Scrutinizer for conducting the Postal Ballot process. The Company has appointed Mr. Rakesh Bha